Headlines

Bristol Myers Squibb (BMY) said a trial met its primary endpoint of overall response rate and key secondary endpoint of complete response rate in a heavily pretreated patient population exposed to a prior BCMA-targeted therapy

Newsquawk Staff ·

Bristol Myers Squibb (BMY) said a trial met its primary endpoint of overall response rate and key secondary endpoint of complete response rate in a heavily pretreated patient population exposed to a prior BCMA-targeted therapy.

Related headlines